157 related articles for article (PubMed ID: 32284763)
1. Cyclooxygenase-2 mediates gefitinib resistance in non-small cell lung cancer through the EGFR/PI3K/AKT axis.
Deng QF; Fang QY; Ji XX; Zhou SW
J Cancer; 2020; 11(12):3667-3674. PubMed ID: 32284763
[TBL] [Abstract][Full Text] [Related]
2. Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway.
Wang B; Jiang H; Wang L; Chen X; Wu K; Zhang S; Ma S; Xia B
Oncol Lett; 2017 May; 13(5):3494-3500. PubMed ID: 28529576
[TBL] [Abstract][Full Text] [Related]
3. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
[TBL] [Abstract][Full Text] [Related]
4. Effects of hyperinsulinemia on acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor via the PI3K/AKT pathway in non-small cell lung cancer cells
Chiu HY; Chiang CM; Yeh SP; Jong DS; Wu LS; Liu HC; Chiu CH
Oncol Lett; 2020 Nov; 20(5):206. PubMed ID: 32963612
[TBL] [Abstract][Full Text] [Related]
5. Long Noncoding RNA LINC00460 Promotes the Gefitinib Resistance of Nonsmall Cell Lung Cancer Through Epidermal Growth Factor Receptor by Sponging miR-769-5p.
Ma G; Zhu J; Liu F; Yang Y
DNA Cell Biol; 2019 Feb; 38(2):176-183. PubMed ID: 30601026
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of CTEN is associated with gefitinib resistance in non-small cell lung cancer.
Lu X; Zhang Y; Pan Y; Cao M; Zhou X; Zhang T
Oncol Lett; 2021 Jan; 21(1):40. PubMed ID: 33262832
[TBL] [Abstract][Full Text] [Related]
7. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
Zheng R; Jiang H; Li J; Liu X; Xu H
Curr Cancer Drug Targets; 2017; 17(4):376-385. PubMed ID: 28093061
[TBL] [Abstract][Full Text] [Related]
8. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
[TBL] [Abstract][Full Text] [Related]
9. FGFR1 Induces Acquired Resistance Against Gefitinib By Activating AKT/mTOR Pathway In NSCLC.
Zhang D; Han LL; Du F; Liu XM; Li J; Wang HH; Song MH; Li Z; Li GY
Onco Targets Ther; 2019; 12():9809-9816. PubMed ID: 31819480
[TBL] [Abstract][Full Text] [Related]
10. Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer.
Pan H; Jiang T; Cheng N; Wang Q; Ren S; Li X; Zhao C; Zhang L; Cai W; Zhou C
Oncotarget; 2016 Aug; 7(31):49948-49960. PubMed ID: 27409677
[TBL] [Abstract][Full Text] [Related]
11. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.
Engelman JA; Jänne PA; Mermel C; Pearlberg J; Mukohara T; Fleet C; Cichowski K; Johnson BE; Cantley LC
Proc Natl Acad Sci U S A; 2005 Mar; 102(10):3788-93. PubMed ID: 15731348
[TBL] [Abstract][Full Text] [Related]
12. Targeting c-kit inhibits gefitinib resistant NSCLC cell growth and invasion through attenuations of stemness, EMT and acquired resistance.
Zhou Y; Wang L; Sun Z; Zhang J; Wang X
Am J Cancer Res; 2020; 10(12):4251-4265. PubMed ID: 33414998
[TBL] [Abstract][Full Text] [Related]
13. Integrin β1-mediated acquired gefitinib resistance in non-small cell lung cancer cells occurs via the phosphoinositide 3-kinase-dependent pathway.
Deng QF; Su BO; Zhao YM; Tang L; Zhang J; Zhou CC
Oncol Lett; 2016 Jan; 11(1):535-542. PubMed ID: 26870244
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of high-dose pulsatile gefitinib in non-small-cell lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.
Wan Y; Yuan Y; Pan Y; Zhang Y
Exp Ther Med; 2017 Jun; 13(6):3067-3074. PubMed ID: 28587381
[TBL] [Abstract][Full Text] [Related]
15. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA LOC554202 promotes acquired gefitinib resistance in non-small cell lung cancer through upregulating miR-31 expression.
He J; Jin S; Zhang W; Wu D; Li J; Xu J; Gao W
J Cancer; 2019; 10(24):6003-6013. PubMed ID: 31762810
[TBL] [Abstract][Full Text] [Related]
17. Sensitization of Non-Small Cell Lung Cancer Cells to Gefitinib and Reversal of Epithelial-Mesenchymal Transition by Aloe-Emodin
Peng M; Zheng Z; Chen S; Fang L; Feng R; Zhang L; Tang Q; Liu X
Front Oncol; 2022; 12():908031. PubMed ID: 35677158
[TBL] [Abstract][Full Text] [Related]
18. Oridonin inhibits gefitinib-resistant lung cancer cells by suppressing EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways.
Xiao X; He Z; Cao W; Cai F; Zhang L; Huang Q; Fan C; Duan C; Wang X; Wang J; Liu Y
Int J Oncol; 2016 Jun; 48(6):2608-18. PubMed ID: 27082429
[TBL] [Abstract][Full Text] [Related]
19. ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC.
Zhao H; Huang Y; Shi J; Dai Y; Wu L; Zhou H
Front Pharmacol; 2018; 9():1312. PubMed ID: 30515095
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
